[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:btk-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"BTK Gene",6,5,[8,16,23,29,35,41],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07673367","Nemtabrutinib With CAR T Therapy in Relapsed\u002FRefractory Mantle Cell Lymphoma",[12],"Phase 2","RECRUITING","2026-08-26T02:17:30.145302Z","2026-07-05T03:45:20.434417Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07321652","Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL\u002FSLL",[20],"Phase 3","2026-08-26T02:19:14.560989Z","2026-06-17T02:29:30.059389Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07277231","A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia",[20],"2026-08-26T02:17:10.213717Z","2026-06-04T01:30:07.896715Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06863402","Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype",[12],"2026-08-26T02:15:54.846520Z","2026-07-24T01:27:14.890802Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT07685717","Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia",[12],"2026-08-26T02:17:20.511551Z","2026-07-19T19:36:05.150027Z",{"nct_id":42,"title":43,"phases":44,"status":46,"updated_at":47,"content_modified":48},"NCT03331198","Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)",[45],"Phase 1\u002FPhase 2","ACTIVE_NOT_RECRUITING","2026-08-03T02:36:24.364783Z","2026-05-05T02:43:29.139125Z"]